Clinicopathological features of recurrent papillary thyroid cancer

Diagnostic Pathology

Haifeng Hou¹  Peifeng Li²  Xiaoxuan Zhang⁴  Xinli Wang³  Jian Zhu⁵ 

[1] Department of Statistics, Taishan Medical College, Taian 271000, China;Department of Pathology, General Hospital of Jinan Military Command, 25 Shifan Road, Jinan 250031, Tianqiao District, China;Department of Pathology, Affiliated Hospital of Taishan Medical College, Taian 271000, China;Medical Administration Division, General Hospital of Jinan Military Command, Jinan 250031, China;Department of Thyroid and Breast Surgery, General Hospital of Jinan Military Command, Jinan 250031, China

关键词: Recurrence;    Pathological subtype;    Papillary thyroid cancer;    Initial surgery approach;    Clinicopathological features;   

Others  :  1219334
DOI  :  10.1186/s13000-015-0346-5

 received in 2015-01-20, accepted in 2015-07-09,  发布年份 2015

【 摘 要 】

Background

To investigate the clinicopathological features of recurrent papillary thyroid carcinoma (PTC).

Methods

A retrospective analysis on clinical and pathological data of 34 patients with recurrent PTC was carried out. A total of 281 patients with non-recurrent PTC during the same time period were chosen as the control group.

Results

Patients were divided into three groups according to the pathological subtype. The number of patients belonging to Groups 1, 2, and 3 were 28, 154, and 133, respectively. 78 patients underwent partial or whole thyroidectomy, 151 cases underwent thyroidectomy combining neck regional lymph node dissection, and 86 patients underwent thyroidectomy combining modified or radical neck dissection. Univariate analysis showed that PTC recurrence was associated with tumor size, extrathyroid invasion, initial surgery approach, lymph node metastasis, and pathological subtype (P < 0.05). Patient age, gender, complication with Hashimoto's thyroiditis, and multifocality were unrelated to PTC recurrence (P > 0.05). Multivariate analysis showed that initial surgery approach and pathological subtype perform important functions in PTC recurrence (P < 0.001). Initial surgery approach presented a negative correlation with PTC recurrence (β = −0.320, OR = 0.726). The pathological subtype was also related to PTC recurrence (β = 0.923, OR = 2.517).

Conclusion

PTC patients without neck dissection showed greater likelihood of postoperative recurrence. Patients with the tall cell, columnar cell, diffuse sclerosing, and oncocytic variants showed a higher propensity for PTC recurrence after operation compared with those who did not. Tumor volume, extrathyroid invasion, and multiple lymph node metastases at the time of initial operation were also significantly related to postoperative recurrence. Follow-up supervision must be enhanced after initial treatment to mitigate PTC recurrence in susceptible patients. Effective and standard treatments must be adopted immediately after the discovery of recurrence.

【 授权许可】

   
2015 Zhu et al.

【 参考文献 】

• [1]Giordano D, Frasoldati A, Kasperbauer JL, Gabrielli E, Pernice C, Zini M, Pedroni C, Cavuto S, Barbieri V. Lateral neck recurrence from papillary thyroid carcinoma: predictive factors and prognostic significance. Laryngoscope. 2014.
• [2]Lee CW, Roh JL, Gong G, Cho KJ, Choi SH, Nam SY, Kim SY. Risk factors for recurrence of papillary thyroid carcinoma with clinically node-positive lateral neck. Ann Surg Oncol. 2015; 22(1):117-24.
• [3]Lang BH, Lee GC, Ng CP, Wong KP, Wan KY, Lo CY. Evaluating the morbidity and efficacy of reoperative surgery in the central compartment for persistent/recurrent papillary thyroid carcinoma. World J Surg. 2013; 37(12):2853-9.
• [4]Londero SC, Krogdahl A, Bastholt L, Overgaard J, Trolle W, Pedersen HB, Bentzen J, Schytte S, Christiansen P, Godballe C. Papillary thyroid microcarcinoma in Denmark 1996–2008: a national study of epidemiology and clinical significance. Thyroid. 2013; 23(9):1159-64.
• [5]Ardito G, Revelli L, Giustozzi E, Salvatori M, Fadda G, Ardito F, Avenia N, Ferretti A, Rampin L, Chondrogiannis S, Colletti PM, Rubello D. Aggressive papillary thyroid microcarcinoma: prognostic factors and therapeutic strategy. Clin Nucl Med. 2013; 38(1):25-8.
• [6]Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19(11):1167-214.
• [7]Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994; 97(5):418-28.
• [8]Cunningham MP, Duda RB, Recant W, Chmiel JS, Sylvester JA, Fremgen A. Survival discriminants for differentiated thyroid cancer. Am J Surg. 1990; 160(4):344-7.
• [9]Monacelli M, Lucchini R, Polistena A, Triola R, Conti C, Avenia S, Di Patrizi MS, Barillaro I, Boccolini A, Sanguinetti A, Avenia N. Total thyroidectomy and central lymph node dissection. Experience of a referral centre for endocrine surgery. G Chir. 2014; 35(5–6):117-21.
• [10]Delogu D, Pisano IP, Pala C, Pulighe F, Denti S, Cossu A, Trignano M. Prophylactic central neck lymphadenectomy in high risk patients with T1 or T2 papillary thyroid carcinoma: is it useful? Ann Ital Chir. 2014; 85(3):225-9.
• [11]Delellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and Genetics Tumours of Endocrine Organs. IARC press, Lyon; 2003.
• [12]Roman S, Sosa JA. Aggressive variants of papillary thyroid cancer. Curr Opin Oncol. 2013; 25(1):33-8.
• [13]Kuo CS, Tang KT, Lin JD, Yang AH, Lee CH, Lin HD. Diffuse sclerosing variant of papillary thyroid carcinoma with multiple metastases and elevated serum carcinoembryonic antigen level. Thyroid. 2012; 22(11):1187-90.
• [14]Evans WD. De-differentiation of papillary thyroid carcinoma into squamous cell carcinoma. A case of coexistence within an excised neck lesion. BMJ Case Rep 2012, 2012. doi:. 10. 1136/bcr-2012-007707 webcite
• [15]Zidan J, Karen D, Stein M, Rosenblatt E, Basher W, Kuten A. Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival. Cancer. 2003; 97(5):1181-5.
• [16]Melcescu E, Horton WB, Pitman KT, Vijayakumar V, Koch CA. Euthyroid Graves' orbitopathy and incidental papillary thyroid microcarcinoma. Hormones (Athens). 2013; 12(2):298-304.
• [17]Boone RT, Fan CY, Hanna EY. Well-differentiated carcinoma of the thyroid. Otolaryngol Clin North Am. 2003; 36(1):73-90.
• [18]Shoup M, Stojadinovic A, Nissan A, Ghossein RA, Freedman S, Brennan MF, Shah JP, Shaha AR. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg. 2003; 197(2):191-7.
• [19]Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A. Clinical significance of metastasis to the central compartment from papillary microcarcinoma of the thyroid. World J Surg. 2006; 30(1):91-9.
• [20]Watkinson JC, Franklyn JA, Olliff JF. Detection and surgical treatment of cervical lymph nodes in differentiated thyroid cancer. Thyroid. 2006; 16(2):187-94.
• [21]Untch BR, Palmer FL, Ganly I, Patel SG, Michael Tuttle R, Shah JP, Shaha AA. Oncologic outcomes after completion thyroidectomy for patients with well-differentiated thyroid carcinoma. Ann Surg Oncol. 2014; 21(4):1374-8.
• [22]Nixon IJ, Ganly I, Patel SG, Palmer FL, Whitcher MM, Tuttle RM, Shaha A, Shah JP. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery. 2012; 151(4):571-9.